# A 6 Week Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of GK1-399 in Type 2 Diabetes

> **NCT01474083** · PHASE1,PHASE2 · COMPLETED · sponsor: **vTv Therapeutics** · enrollment: 248 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** GK1-399 (formerly TTP399)
- **DRUG:** GK1-399 (formerly TTP399)
- **DRUG:** GK1-399 (formerly TTP399)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01474083
- **Lead sponsor:** vTv Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11
- **Primary completion:** 2012-08
- **Final completion:** 2012-09
- **Target enrollment:** 248 (ACTUAL)
- **Last updated:** 2013-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01474083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01474083, "A 6 Week Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of GK1-399 in Type 2 Diabetes". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01474083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*